BPC-157 Oral (50 mg / 100 × 500 mcg tablets) — Research Overview
BPC-157 Oral is a tablet-format presentation of the gastric pentadecapeptide, supplying 100 tablets of 500 mcg each (50 mg total). It supports research into the oral bioavailability of BPC-157 — an area of particular interest because the compound is noted for stability in the digestive tract.
Mechanism & Research Applications
BPC-157 is studied for angiogenesis, growth factor signalling, and gastrointestinal mucosal integrity. The oral format is specifically relevant to researchers examining gut-focused models and oral delivery pharmacokinetics.
The tablet format removes the reconstitution step, making it convenient for oral-administration research designs. This is a specialised presentation within NuMe’s healing peptides range in Canada.
Specifications
100 × 500 mcg tablets (50 mg total) | ≥99% purity | Batch-specific COA included
Quality & Sourcing in Canada
NuMe supplies BPC-157 Oral (50 mg / 100 × 500 mcg tablets) as part of its catalogue of healing peptides in Canada and buy peptides in Canada. Every batch is verified to ≥99% purity by HPLC, ships domestically from within Canada (typically 1–3 business days), and includes a batch-specific Certificate of Analysis. Free shipping applies to orders over $300 CAD.
Frequently Asked Questions
Why is BPC-157 available in an oral format?
BPC-157 is noted in research for its stability in the digestive tract, which makes the oral tablet format useful for studying oral bioavailability and gut-focused models.
How many tablets are included?
Each unit contains 100 tablets of 500 mcg, for 50 mg of BPC-157 total, supplied with a batch-specific COA.
Is oral BPC-157 stocked in Canada?
This is a specialised item in NuMe’s Canadian catalogue; stock can vary. It is sold for research use only.
For Research Purposes Only. This product is intended exclusively for laboratory research and in-vitro testing. It is not for human or veterinary use, consumption, or any therapeutic application.





Reviews
There are no reviews yet.